Drug Profile
Lipoic acid choline ester - Novartis
Alternative Names: EV-06; Lipoic acid choline ester 1.5%; Lipoic acid choline ester chloride; Thioctic acid choline ester; UNR 844; UNR844-ClLatest Information Update: 30 Jan 2023
Price :
$50
*
At a glance
- Originator Encore Vision
- Developer Novartis
- Class Carboxylic acids; Coenzymes; Esters; Eye disorder therapies; Fatty acids; Hepatoprotectants; Quaternary ammonium compounds; Sulfhydryl compounds; Thiophenes
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Presbyopia
Most Recent Events
- 30 Jan 2023 NCT04806503; CTP-Push; Trial is already discontinued on the basis of MR hence not covered
- 28 Nov 2022 Discontinued - Phase-II for Presbyopia in Canada, Japan, Australia, USA (Ophthalmic)
- 14 Oct 2022 Novartis completes a phase II trial in Presbyopia in USA, Australia, Canada and Japan (Ophthalmic) (NCT04806503)